Clolar^® (clofarabine)

Bibliographical Information:

Drug Name	Generic Name	Studied Indications or Disease	Approved U.S. Drug Label
Clolar®	clofarabine	Pediatric relapsed or refractory acute lymphoblastic leukemia (ALL)	Prescribing Info

Protocol CLO212

Bonate PL, Craig A, Gaynon P, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004;44(11):1309-1322.

Jeha S, Razzouk B, Rytting M, et al. Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. Proc Amer Soc Clin Oncol 2004;22(14s):800s. Abstract 8504.

Jeha S, Razzouk B, Gaynon P, et al. Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Blood 2004;103(12):196a. Abstract 684.

Jeha S, Gaynon P, Steinherz P, et al. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2003;102(11):881a. Abstract 3277.

Jeha S, Steinherz P, Razzouk B, et al. A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous or lymphoblastic leukemia. Proc Amer Soc Clin Oncol 2003;22:809. Abstract 3251. 

Jeha S, Steinherz P, Altman A, et al. A phase II, open-label study of Clofarex in pediatric patients with refractory or relapsed acute myelogenous or lymphoblastic leukemia. Blood 2002;100(11):271b. Abstract 4616.

Corey SJ, Elopre M, Weitman S, et al. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatric Hematol 2005;27(3):166-168.

Jeha S, Gaynon Paul S, Razzouk Bassem I, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Onc 2006;24(12):1917-1923.